Shefa Neurosciences Research Center

Tehrān, Iran

Shefa Neurosciences Research Center

Tehrān, Iran

Time filter

Source Type

Abolfazli R.,Shefa Neurosciences Research Center | Abolfazli R.,Tehran University of Medical Sciences | Samadzadeh S.,Shefa Neurosciences Research Center | Samadzadeh S.,Tehran University of Medical Sciences | And 9 more authors.
Journal of the Neurological Sciences | Year: 2014

Allele frequency among patients with positive history of multiple sclerosis disease showed that DRB1 11 allele has a significantly low rate in MS patients with positive history compare to other patients. In contrast DRB1 15 allele has a significantly high rate in MS patients with positive history compare to other patients. The frequencies of other alleles were not significantly different between the MS patients and the control group. The frequency of the HLA-DRB1∗ 11/15 genotype detected in the present study showed that this genotype is partially significant factor for MS susceptibility and development in Iran. © 2014 Elsevier B.V.


Samadzadeh S.,Shefa Neurosciences Research Center | Samadzadeh S.,Tehran University of Medical Sciences | Tabibian E.,Tehran University of Medical Sciences | Sabokbar T.,Qom University of Medical Sciences | And 7 more authors.
Journal of the Neurological Sciences | Year: 2015

Abstract Background & objectives The role of human leukocyte antigen (HLA) in clinical response to immunotherapy is not completely known. In this study we evaluated the relationship between HLA-DRB1 genotype, which has been proved to be more common in Iranian MS patients, and clinical response to interferon-beta (IFNβ), which is the most common immunotherapy for relapsing-remitting MS. Design and setting In this study 68 Iranian patients with confirmed diagnosis of RRMS who had been referred to and admitted in Neurology Department of Amiralam and Khatam Hospitals in Tehran were selected. Patients were followed prospectively for 2 years since initiation of therapy and clinical data, including EDSS scores were recorded every 3 months. MRI was performed at the time of diagnosis and each year. Methods HLA-DRB1 typing was performed by polymerase chain reaction (PCR) for all patients and data was analyzed by STATA 12th edition. Results There were 47 (69.1%) responders and 21 (30.9%) non-responders. These two groups were demographically and clinically comparable. Fisher's exact test did not show any difference between HLA-DRB1 allele frequencies in responders and non-responders. Conclusions Our findings confirmed the lack of association between HLA-DRB1 and clinical response to IFNβ among MS patients as previous studies had done. © 2015 Elsevier B.V. All rights reserved.


PubMed | Shefa Neurosciences Research Center, Qom University of Medical Sciences and Tehran University of Medical Sciences
Type: Journal Article | Journal: Journal of the neurological sciences | Year: 2015

The role of human leukocyte antigen (HLA) in clinical response to immunotherapy is not completely known. In this study we evaluated the relationship between HLA-DRB1 genotype, which has been proved to be more common in Iranian MS patients, and clinical response to interferon-beta (IFN), which is the most common immunotherapy for relapsing-remitting MS.In this study 68 Iranian patients with confirmed diagnosis of RRMS who had been referred to and admitted in Neurology Department of Amiralam and Khatam Hospitals in Tehran were selected. Patients were followed prospectively for 2 years since initiation of therapy and clinical data, including EDSS scores were recorded every 3 months. MRI was performed at the time of diagnosis and each year.HLA-DRB1 typing was performed by polymerase chain reaction (PCR) for all patients and data was analyzed by STATA 12th edition.There were 47 (69.1%) responders and 21 (30.9%) non-responders. These two groups were demographically and clinically comparable. Fishers exact test did not show any difference between HLA-DRB1 allele frequencies in responders and non-responders.Our findings confirmed the lack of association between HLA-DRB1 and clinical response to IFN among MS patients as previous studies had done.


Kashani I.R.,Tehran University of Medical Sciences | Hedayatpour A.,Tehran University of Medical Sciences | Pasbakhsh P.,Tehran University of Medical Sciences | Kafami L.,Alborz University of Medical science | And 3 more authors.
Iranian Journal of Medical Sciences | Year: 2015

Background: Progesterone as a sex steroid hormone is thought to affect and prevent demyelination, but its role in promoting myelin repair is far less investigated. In this study, remyelinating potential of progesterone in corpus callosum was evaluated on an experimental model of MS. Methods: In this experimental study, adult male C57BL/6 mice were fed with 0.2% (w/w) cuprizone in ground breeder chow ad libitum for 6 weeks. At day zero, after cuprizone removal, mice were divided randomly into two groups: (a) placebo group which received saline pellet implant, (b) progesterone group, which received progesterone pellet implant. Some mice of the same age were fed with their normal diet to serve as the healthy control group. Two weeks after progesterone administration, Myelin content was assessed by Luxol-fast blue staining. The myelin basic protein (MBP) and proteolipid protein (PLP) expression were assessed using Western blot analysis and the changes in the number of oligodendrocytes and oligodendroglial progenitor cells were assessed by immunohistochemistry (IHC) and flow cytometry. Results: Luxol-fast blue staining revealed enhanced remyelination in the progesterone group when compared with the placebo group. Densitometry measurements of immunoblots demonstrated that MBP and PLP proteins contents were significantly increased in the progesterone group compared with the placebo group. Flow cytometry and IHC analysis showed increases in Olig2 and O4 cells in the progesterone group compared with the placebo group. Conclusion: Overall, our results indicate that progesterone treatment can stimulate myelin production and that it may provide a feasible and practical way for remyelination in diseases such as multiple sclerosis. © 2015, Shiraz University of Medical Sciences. All rights reserved.


PubMed | Shefa Neurosciences Research Center and Tehran University of Medical Sciences
Type: Journal Article | Journal: Iranian journal of medical sciences | Year: 2015

Progesterone as a sex steroid hormone is thought to affect and prevent demyelination, but its role in promoting myelin repair is far less investigated. In this study, remyelinating potential of progesterone in corpus callosum was evaluated on an experimental model of MS.In this experimental study, adult male C57BL/6 mice were fed with 0.2% (w/w) cuprizone in ground breeder chow ad libitum for 6 weeks. At day zero, after cuprizone removal, mice were divided randomly into two groups: (a) placebo group, which received saline pellet implant, (b) progesterone group, which received progesterone pellet implant. Some mice of the same age were fed with their normal diet to serve as the healthy control group. Two weeks after progesterone administration, Myelin content was assessed by Luxol-fast blue staining. The myelin basic protein (MBP) and proteolipid protein (PLP) expression were assessed using Western blot analysis and the changes in the number of oligodendrocytes and oligodendroglial progenitor cells were assessed by immunohistochemistry (IHC) and flow cytometry.Luxol-fast blue staining revealed enhanced remyelination in the progesterone group when compared with the placebo group. Densitometry measurements of immunoblots demonstrated that MBP and PLP proteins contents were significantly increased in the progesterone group compared with the placebo group. Flow cytometry and IHC analysis showed increases in Olig2 and O4 cells in the progesterone group compared with the placebo group.Overall, our results indicate that progesterone treatment can stimulate myelin production and that it may provide a feasible and practical way for remyelination in diseases such as multiple sclerosis.

Loading Shefa Neurosciences Research Center collaborators
Loading Shefa Neurosciences Research Center collaborators